SEC Form 4 · accession 0001144204-19-005041
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael P. Manzo
Officer — Vice President of Engineering
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.48 | Feb 1, 2019 | A | 50,000 | A | — | Feb 1, 2029 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2020, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.